Cocrystal Pharma (8CC) Stock Statistics & Valuation Metrics
Total Valuation
Cocrystal Pharma has a market cap or net worth of EUR 17.10M. The enterprise value is EUR 13.57M.
- Market Cap
- EUR 17.10M
- Enterprise Value
- EUR 13.57M
Share Statistics
Cocrystal Pharma has 19,263,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 19,263,200
- Owned by Insiders
- 32.70%
- Owned by Institutions
- 4.09%
Financial Efficiency
Cocrystal Pharma’s return on equity (ROE) is -1.39 and return on invested capital (ROIC) is -115.10%.
- Return on Equity (ROE)
- -1.39
- Return on Assets (ROA)
- -0.91
- Return on Invested Capital (ROIC)
- -115.10%
- Return on Capital Employed (ROCE)
- -1.20
- Revenue Per Employee
- 0
- Profits Per Employee
- -883.10K
- Employee Count
- 10
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Cocrystal Pharma is -1.24. Cocrystal Pharma’s PEG ratio is -0.03.
- PE Ratio
- -1.24
- PS Ratio
- 58.08
- PB Ratio
- 13.14
- Price to FCF
- -2.35
- Price to Operating Cash Flow
- -1.69
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Cocrystal Pharma had revenue of 0 and earned -8.83M in profits. Earnings per share was -0.78.
- Revenue
- 0
- Gross Profit
- -5.05M
- Operating Income
- -9.02M
- Pretax Income
- -8.83M
- Net Income
- -8.83M
- EBITDA
- -8.46M
- Earnings Per Share (EPS)
- -0.78
Cash Flow
In the last 12 months, operating cash flow was -8.14M and capital expenditures -12,561, giving a free cash flow of -8.15M billion.
- Operating Cash Flow
- -8.14M
- Free Cash Flow
- -8.15M
- Free Cash Flow per Share
- -0.59
Dividends & Yields
Cocrystal Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -42.54%
- Earnings Yield
- -72.44%
Stock Price Statistics
- Beta
- 0.87
- 52-Week Price Change
- -13.40%
- 50-Day Moving Average
- 0.94
- 200-Day Moving Average
- 0.93
- Relative Strength Index (RSI)
- 40.90
- Average Volume (3m)
- 1,193
Important Dates
Cocrystal Pharma upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 17, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Cocrystal Pharma as a current ratio of 3.68, with Debt / Equity ratio of 23.77%
- Current Ratio
- 3.68
- Quick Ratio
- 3.68
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.65
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Cocrystal Pharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Cocrystal Pharma EV to EBITDA ratio is -1.85, with an EV/FCF ratio of -2.25.
- EV to Sales
- 55.57
- EV to EBITDA
- -1.85
- EV to Free Cash Flow
- -2.25
- EV to Operating Cash Flow
- -2.25
Balance Sheet
Cocrystal Pharma has EUR 2.17M in cash and marketable securities with EUR 1.34M in debt, giving a net cash position of EUR 828.00K billion.
- Cash & Marketable Securities
- EUR 2.17M
- Total Debt
- EUR 1.34M
- Net Cash
- EUR 828.00K
- Net Cash Per Share
- EUR 0.04
- Tangible Book Value Per Share
- EUR 0.08
Margins
Gross margin is 100.00%, with operating margin of -3063.64%, and net profit margin of -3011.52%.
- Gross Margin
- 100.00%
- Operating Margin
- -3063.64%
- Pretax Margin
- -3011.52%
- Net Profit Margin
- -3011.52%
- EBITDA Margin
- -2996.36%
- EBIT Margin
- -3011.52%
Analyst Forecast
The average price target for Cocrystal Pharma is EUR 5.37, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 5.37
- Price Target Upside
- 539.39% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 42.72%